(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 April 2004 (15.04.2004)

PCT

(10) International Publication Number
WO 2004/030635 A3

(51) International Patent Classification[7]: C07D 209/04, A61K 31/404, 31/495

(21) International Application Number: PCT/US2003/031721

(22) International Filing Date: 2 October 2003 (02.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

| | | |
|---|---|---|
| 60/415,981 | 3 October 2002 (03.10.2002) | US |
| 60/440,234 | 14 January 2003 (14.01.2003) | US |
| 60/443,752 | 29 January 2003 (29.01.2003) | US |
| 60/463,818 | 17 April 2003 (17.04.2003) | US |
| 60/466,983 | 30 April 2003 (30.04.2003) | US |
| 60/479,295 | 17 June 2003 (17.06.2003) | US |

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

| | |
|---|---|
| US | us60/415,981 (CIP) |
| Filed on | 3 October 2002 (03.10.2002) |
| US | 60/440,234 (CIP) |
| Filed on | 14 January 2003 (14.01.2003) |
| US | 60/443,752 (CIP) |
| Filed on | 29 January 2003 (29.01.2003) |
| US | 60/463,818 (CIP) |
| Filed on | 17 April 2003 (17.04.2003) |
| US | 60/466,983 (CIP) |
| Filed on | 30 April 2003 (30.04.2003) |
| US | 60/479,295 (CIP) |
| Filed on | 17 June 2003 (17.06.2003) |

(71) Applicant *(for all designated States except US)*: **TARGEGEN, INC.** [US/US]; 9393 Towne Centre Drive, Suite 120, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **WRASIDLO, Wolfgang** [US/US]; 307 Prospect Street, La Jolla, CA 92037 (US). **DOUKAS, John** [US/US]; 299 Triton Circle, Encinitas, CA 92024 (US). **ROYSTON, Ivor** [US/US]; 1515 El Camino del Teatro, La Jolla, CA 92037 (US). **NORONHA, Glenn** [IN/US]; 4860 Baroque Terrace, Oceanside, CA 92057 (US). **HOOD, John, D.** [US/US]; 10831 Vereda Sol del Dios, San Diego, CA 92130 (US). **DNEPROVSKAIA, Elena** [RU/US]; 4070 Huerfano Ave. #205, San Diego, CA 92117 (US). **GONG, Xianchang** [CN/US]; 9505 Genesee Ave. Apt. 524, San Diego, CA 92121 (US). **SPLITTGERBER, Ute** [DE/US]; 4800 La Cruz Drive, La Mesa, CA 91941 (US). **ZHAO, Ningning** [CN/US]; 17835 Ardisia Court, San Diego, CA 92127 (US).

(74) Agent: **HAILE, Lisa, A.**; Gray Cary Ware & Freidenrich LLP, Suite 1100, 4365 Executive Drive, San Diego, CA 92121-2133 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report: 12 August 2004

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF

(57) Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.

WO 2004/030635 A3